WHO ICTRP trial
METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the…
CTIS2022-500027-76-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2022-500027-76-00 |
|---|---|
| Public title | METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organs |
| Scientific title | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer – Shaping Anti-Tumor Immunity by Oxaliplatin - METIMMOX-2 |
| Primary sponsor | Akershus University Hospital |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use - (Phase IV): no |
| Countries | Norway |
| Conditions | Colorectal cancer;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Adrenalin Aguettant 1 mg/ml injeksjonsvæske, oppløsning i ferdigfylt sprøyte,Product Code: PRD8154283,Pharmaceutical Form: SOLUTION FOR INJECTION,Other descriptive name: ,Strength: Epinephrine 5mg / 5mL,Product Name… |
| Registration date | Feb 20, 2022 |
| Target size | 40 |
| Secondary IDs | NCT05504252 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: